Copyright
©The Author(s) 2023.
World J Hepatol. Aug 27, 2023; 15(8): 964-972
Published online Aug 27, 2023. doi: 10.4254/wjh.v15.i8.964
Published online Aug 27, 2023. doi: 10.4254/wjh.v15.i8.964
Figure 1 Flowchart of study participants.
CHB: Chronic hepatitis B; TAF: Tenofovir alafenamide; ETV: Entecavir; TCHO: Total cholesterol; HDL: High density lipoprotein; LDL: Low-density lipoprotein; TG: Triglycerides.
Figure 2 Nomogram plot predicted the probability of the elevated total cholesterol level for individual patients receiving tenofovir alafenamide therapy.
BMI: Body mass index; CK-MB: Creatine kinase-MB isoenzyme; TCHO: Total cholesterol.
- Citation: Lai RM, Lin S, Wang MM, Li N, Zhou JH, Lin XY, Chen TB, Zhu YY, Zheng Q. Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients. World J Hepatol 2023; 15(8): 964-972
- URL: https://www.wjgnet.com/1948-5182/full/v15/i8/964.htm
- DOI: https://dx.doi.org/10.4254/wjh.v15.i8.964